Hepatitis C Treatment Options - Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2005 Financial Results

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2005 Financial Results
[Press Release] PR Newswire via Yahoo! Finance - Feb 23 1:00 PM
Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis, other serious infections, and cancer, today reported its financial results for the fourth quarter and year ended December 31, 2005.Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 12:56 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Feb 23 5:30 AM
Coley Pharmaceutical Group, Inc. today announced the initiation of a randomized Phase II clinical study of Actilon for the treatment of patients with chronic Hepatitis C infection.Save to My Web